Diligence memo · auto-generated · as of July 2, 2026
Invert, Inc.
Invert, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Invert, Inc. operates in Biotech, based in DOVER, CA, USA; Remote. Data analytics software for biomanufacturing.
Sub-sector tags: Biotech, Cellular Agriculture, Machine Learning, Synthetic Biology, data/analytics.
Capital & rounds (filed)filed
Invert, Inc. has raised $20M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2024-06-25.
Most recent recorded round closed around 2024-06-25.
Valuation (modeled)modeled
Provath models Invert, Inc. at approximately $145M (range $40M–$260M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.94× the median modeled value of Series B Biotech companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (94% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.0 yr ago; this sector typically re-raises about every 11 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 90% of Biotech peers (233 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Watchmaker Genomics, Inc., Mytos, Inc., ZBiotics Co, Siren Biotechnology, Inc., AgNovos Bioscience, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.